Saturday 17 October 2026 Export NDRA’s income statement to Excel — free account

ENDRA Life Sciences Inc.

In the quarter to June 2026, EPS grew 107.0% and free cash flow grew 15.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

4.74 0.36 −7.06%

Follow NDRA

Alert me

Market cap: $7.7M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 6/9
Altman Z: −5.26
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 46.37%

Capital & Financial Ratios $m

Market Cap 7.65

Revenue 0.36

Net Income (5.92)

Free Cash Flow (7.84)

Net Debt (5.54)

Current Ratio 7.10

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.70)

P/S ratio 17.54

P/B ratio 0.99

Past 5Y EPS Growth —

This Y EPS Growth 60.36%

Next Y EPS Growth 14.12%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 33.26%

10-year low 10-year high

P/B against its own 10 years 14.46%

10-year low 10-year high

EV/Sales against its own 10 years 3.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	3	1	6
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	3	3	1	6

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	0	—	—	—
Other	—	—	—	—
	1	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(20.62%)	(32.05%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’18	0	—	—	—	0
’17	—	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	(1)	(2)	(5)
’24	(2)	(2)	(2)	(2)	(7)
’23	(3)	(2)	(3)	(2)	(10)
’22	(3)	(3)	(3)	(3)	(13)
’21	(3)	(3)	(3)	(3)	(11)
’20	(3)	(3)	(2)	(2)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	(1)	(5)	(8)
’24	(2)	(2)	(2)	(2)	(7)
’23	(3)	(2)	(3)	(2)	(10)
’22	(3)	(3)	(3)	(3)	(13)
’21	(3)	(3)	(3)	(3)	(11)
’20	(3)	(3)	(2)	(2)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.09)	0.06	—	—	—
’25	(1.86)	(1.71)	(2.10)	(3.25)	(8.93)
’24	(454.54)	(139.86)	(9.54)	(20.78)	(56.94)
’23	(1.63k)	(751.75)	(699.30)	(297.20)	(2.76k)
’22	(2.45k)	(2.10k)	(1.75k)	(1.82k)	(7.97k)
’21	(2.10k)	(2.80k)	(2.10k)	(2.45k)	(9.79k)
’20	(10.14k)	(6.99k)	(5.24k)	(3.50k)	(22.03k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	75,250.00	50,400.00	21,735.00	20,965.00	24,150.00	5,528.25	1,522.50	4.01	2.90	Analyst estimates 2026–2028 Powerpack
	High	—	205,800.00	201,250.00	122,010.00	78,750.00	108,500.00	27,650.00	9,432.50	3,412.50	11.96
People
People	Employees	8	13	11	15	18	22	21	21	21	11
	Revenue/emp, $m	0.06	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	1	0	0	—	—	—	—	—	—	—
	Gross margin, %	54.25	50.85	100.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(3)	(5)	(10)	(13)	(12)	(11)	(13)	(10)	(12)	(7)
	EBT margin, %	(538.29)	(1,529.29)	(158,004.84)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(3)	(5)	(10)	(13)	(12)	(11)	(13)	(10)	(12)	(7)
	Depreciation	1	1	1	3	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.00	3,516.00	62.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(134,219.70)	(68,181.82)	(75,874.13)	(81,818.18)	(22,027.97)	(9,790.21)	(7,972.03)	(2,762.24)	(56.94)	(8.93)
	Cash flow	0.00	(33,009.00)	(77,025.00)	(42,944.50)	(21,493.20)	(9,268.67)	(7,511.41)	(2,652.44)	(36.64)	(6.59)
	Capex	0.00	(79.00)	(1,000.00)	(218.00)	(150.60)	(37.50)	(119.18)	(6.86)	(0.06)	(3.83)
	Free cash flow	0.00	(33,088.00)	(78,025.00)	(43,162.50)	(21,643.80)	(9,306.17)	(7,630.59)	(2,659.31)	(36.70)	(10.42)
	Book value	0.00	52,755.00	62,482.00	23,803.50	14,338.60	8,986.92	4,237.94	1,571.94	12.68	2.87
	Shares, m	0	0	0	0	0	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	—	—	—	—	—	—	—
	P/S	0.00	19.97	14.67	—	—	—	—	—	—	—
	P/B	1.75	3.28	0.84	—	—	—	—	—	—	—
	EV/Sales	0.00	13.51	(3.41)	—	—	—	—	—	—	—
	EV/FCF	(3.19)	(3.54)	0.16	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(1)	(3)	(8)	(9)	(11)	(11)	(13)	(10)	(7)	(5)
	Capex	—	0	0	0	0	0	0	0	0	(3)
	Free cash flow	(1)	(3)	(8)	(9)	(11)	(11)	(13)	(10)	(7)	(8)
Balance, $m
Balance, $m	Working capital	(1)	5	6	4	7	11	6	2	3	0
	Total debt	1	—	—	1	0	0	0	0	—	—
	Net debt	1	(6)	(6)	(5)	(7)	(9)	(5)	(3)	(3)	(1)
	Shareholders’ equity	(1)	5	6	5	7	11	7	6	3	2
Returns, %
Returns, %	ROA	(83.92)	(162.58)	(146.80)	(243.43)	(152.07)	(104.92)	(119.01)	(125.53)	(205.38)	(169.21)
	ROIC	0.00	0.00	0.00	0.00	(2,021.57)	(484.39)	(350.85)	(230.43)	0.00	(240.50)
	ROE	(126.68)	(245.43)	(170.02)	(318.39)	(203.20)	(126.46)	(146.53)	(156.42)	(280.02)	(291.56)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2018 · latest quarter Mar 2018

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PMD Psychemedics Corporation	$15.7M	— (loss-making)	— (loss-making)	−11.46% (below 0%: shrinking)	n/m	+57.45% (above 0%: growing)	31.37%	3.80%	Compare
ADVB Advanced Biomed Inc.	$8.1M	0.8×	—	—	n/m	−101.33% (below 0%: shrinking)	—	0.00%	Compare
NDRA ENDRA Life Sciences Inc.	$7.7M	— (loss-making)	— (loss-making)	−98.80% (below 0%: shrinking)	n/m	+15.04% (above 0%: growing)	0.00%	0.00%
XWEL XWELL, Inc.	$7.5M	— (loss-making)	— (loss-making)	−7.08% (below 0%: shrinking)	n/m	−43.02% (below 0%: shrinking)	41.26%	(29.45%)	Compare
TTOO T2 Biosystems, Inc.	$6.5M	— (loss-making)	— (loss-making)	+34.85% (above 0%: growing)	n/m	+53.36% (above 0%: growing)	(106.60%)	(511.89%)	Compare
BIAF bioAffinity Technologies, Inc.	$5.1M	— (loss-making)	— (loss-making)	+18.99% (above 0%: growing)	n/m	−23.69% (below 0%: shrinking)	27.98%	(220.77%)	Compare
DMTKQ DermTech, Inc.	$3.3M	— (loss-making)	— (loss-making)	+10.58% (above 0%: growing)	n/m	+24.87% (above 0%: growing)	18.54%	(533.37%)	Compare
NOTVQ Inotiv, Inc.	$2.8M	— (loss-making)	— (loss-making)	−5.37% (below 0%: shrinking)	n/m	+82.66% (above 0%: growing)	20.95%	(16.41%)	Compare
ISPC iSpecimen Inc.	$2.6M	— (loss-making)	— (loss-making)	−78.70% (below 0%: shrinking)	n/m	−257.73% (below 0%: shrinking)	45.23%	(897.30%)	Compare
Median of peers	$5.8M	—	—	−5.37%	—	+0.59%	27.98%	(125.11%)

All 52 Diagnostics & Research stocks →

ENDRA Life Sciences Inc. (NDRA) key facts

ENDRA Life Sciences Inc. (NDRA) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NDRA traded at $4.74, a market capitalization of $7.7 million.
Return on equity was −291.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.